TY - JOUR T1 - Incretin agents in type 2 diabetes JF - Canadian Family Physician JO - Can Fam Physician SP - 639 LP - 648 VL - 56 IS - 7 AU - Stuart A. Ross AU - Jean-Marie Ekoé Y1 - 2010/07/01 UR - http://www.cfp.ca/content/56/7/639.abstract N2 - OBJECTIVE To evaluate the emerging classes of antihyperglycemic agents that target the incretin pathway, including their therapeutic efficacy and side effect profiles, in order to help identify their place among the treatment options for patients with type 2 diabetes. QUALITY OF EVIDENCE MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews were searched. Most evidence is level I and II. MAIN MESSAGE Two classes of incretin agents are currently available: glucagonlike peptide 1 (GLP1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, both of which lower hyperglycemia considerably without increasing the risk of hypoglycemia. The GLP1 receptor agonists have a greater effect on patients’ glycated hemoglobin A1c levels and cause sustained weight loss, whereas the DPP4 inhibitors are weight-neutral. CONCLUSION The GLP1 and DPP4 incretin agents, promising and versatile antihyperglycemic agents, are finding their way into the therapeutic algorithm for treating type 2 diabetes. They can be used in patients not adequately controlled by metformin monotherapy or as initial therapy in those for whom metformin is contraindicated. ER -